Définitions de la résistance aux antiviraux analogues dans le traitement de l'hépatite chronique B

[1]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[2]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[3]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[4]  F. Zoulim.  New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. , 2005, Journal of hepatology.

[5]  M. Chevallier,et al.  Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. , 2005, Journal of hepatology.

[6]  F. Zoulim.  Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance? , 2004, Antiviral chemistry & chemotherapy.

[7]  F. Zoulim.  Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.

[8]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[9]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[10]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[11]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[12]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[13]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  F. Zoulim,et al.  Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses , 2002, Hepatology.

[15]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[16]  L. Stuyver,et al.  Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.